Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.

NCT05857332 is registered in ClinicalTrials.gov with Hangzhou Sumgen Biotech Co., Ltd. as lead sponsor.

NCT NCT05857332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05857332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.
Lead sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 30, 2023
Completion date
August 30, 2027
Enrollment
60 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced unresectable or metastatic solid tumors